Suppr超能文献

评估女性与男性腺瘤检出率的基准。

Assessment of adenoma detection rate benchmarks in women versus men.

机构信息

Department of Gastroenterology, Mayo Clinic, Jacksonville, FL 32224, USA.

出版信息

Gastrointest Endosc. 2013 Apr;77(4):631-5. doi: 10.1016/j.gie.2012.12.001. Epub 2013 Feb 1.

Abstract

BACKGROUND

Current guidelines suggest screening adenoma detection rates (ADRs) of 15% for average-risk women and 25% for average-risk men.

OBJECTIVE

Determine average-risk screening ADRs and the prevalence of adenomas by location, size, shape, and degree of dysplasia in each sex.

DESIGN

Post hoc analysis of prospectively collected data.

SETTING

Academic center, ambulatory center.

PATIENTS

A total of 864 average-risk patients.

INTERVENTION

Screening colonoscopy.

MAIN OUTCOME MEASUREMENTS

By using a prospectively collected colonoscopy database, we determined the ADRs for each sex and compared them to current medical society guidelines. In patients with adenomas detected, we compared the percentage of proximally located, large, and advanced-pathology adenomas between sexes.

RESULTS

The overall average-risk screening ADR was 33.7% for both sexes combined. Average risks for women and men were significantly higher than guidelines (women: 25.4% vs 15%; P = .0003; men: 41.2% vs 25%; P < .0001). The ADR remained significantly higher for men versus women (P < .0001). Overall advanced-pathology adenoma detection was 12.2% for both sexes combined. There was a significantly higher advanced-pathology ADR for men (15.3%) versus women (8.7%) (P = .003). There was no significant difference between the sexes when age was considered in both advanced-pathology and average-risk ADRs.

LIMITATIONS

Data from the study focused on improving ADRs in an academic setting.

CONCLUSION

The ADR in our study was higher than current benchmarks for both sexes. In patients with at least one adenoma, advanced-pathology adenomas were detected equally among men and women. Although the benefits of achieving supra-benchmark ADRs are unknown, high ADRs may lead to more effective colonoscopy.

摘要

背景

目前的指南建议,对于平均风险的女性,腺瘤检出率(ADR)应达到 15%,对于平均风险的男性,ADR 应达到 25%。

目的

确定男女平均风险筛查 ADR 以及腺瘤的发生率,腺瘤的位置、大小、形状和异型增生程度。

设计

前瞻性收集数据的事后分析。

设置

学术中心、门诊中心。

患者

共有 864 例平均风险患者。

干预措施

筛查结肠镜检查。

主要观察指标

通过使用前瞻性收集的结肠镜检查数据库,我们确定了每一种性别中的 ADR,并将其与当前的医学协会指南进行了比较。在检测到腺瘤的患者中,我们比较了男女之间近端、大腺瘤和高级别病变腺瘤的比例。

结果

男女两性的总体平均风险筛查 ADR 均为 33.7%。女性和男性的平均风险均显著高于指南(女性:25.4%比 15%;P =.0003;男性:41.2%比 25%;P <.0001)。男性的 ADR 仍显著高于女性(P <.0001)。男女两性的总体高级别病变腺瘤检出率为 12.2%。男性(15.3%)高级别病变腺瘤检出率显著高于女性(8.7%)(P =.003)。当考虑到高级别病变和平均风险 ADR 中的年龄时,男女之间无显著性差异。

局限性

该研究的数据重点是提高学术环境中的 ADR。

结论

我们的研究中男女两性的 ADR 均高于当前的基准。在至少有一个腺瘤的患者中,男性和女性的高级别病变腺瘤的检出率相等。尽管达到超基准 ADR 的益处尚不清楚,但高 ADR 可能会导致更有效的结肠镜检查。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验